Former executive at Lonza Group AG
- Salient developments in the C> (cell and gene therapy) manufacturing market, including outsourcing rate, manufacturing economics and supply chain pressures
- Latest M&A, corporate strategy and CAPEX trends among key tier 1 C> CDMO (contract development and manufacturing organisation) incumbents
- Lonza’s (VTX: LONN) C> business unit deep dive – benchmarking vs customer KPC (key purchasing criteria), capacity, cost base and technology analysis
- Lonza C> profitability outlook – ability to improve the clinical vs commercial programme balance and achieve operational efficiencies and improved yields
- Key synergies between Lonza’s Biosciences and C> CDMO divisions
Gain access to Premium Content
Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.